ATE404574T1 - Verfahren zur inhibierung der proliferation von tumorzellen, bei dem platinkomplexe eingesetzt werden - Google Patents

Verfahren zur inhibierung der proliferation von tumorzellen, bei dem platinkomplexe eingesetzt werden

Info

Publication number: ATE404574T1
Authority: AT; Austria
Prior art keywords: proliferation; inhibiting; platinum complexes; tumor cells; complexes
Prior art date: 2003-08-13

Application number

AT04809566T

Other languages

English (en)

Inventor

James Turkson

Richard Jove

Jay Palmer

Heidi Kay

Hua Yu

Original Assignee

Univ South Florida

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-08-13

Filing date

2004-08-13

Publication date

2008-08-15

2004-08-13 Application filed by Univ South Florida filed Critical Univ South Florida

2008-08-15 Application granted granted Critical

2008-08-15 Publication of ATE404574T1 publication Critical patent/ATE404574T1/de

Links

230000002401 inhibitory effect Effects 0.000 title 1
BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical class [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 title 1
230000035755 proliferation Effects 0.000 title 1
210000004881 tumor cell Anatomy 0.000 title 1
230000008827 biological function Effects 0.000 abstract 1
230000005764 inhibitory process Effects 0.000 abstract 1
150000003057 platinum Chemical class 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F15/00—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table
- C07F15/0006—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table compounds of the platinum group
- C07F15/0086—Platinum compounds
- C07F15/0093—Platinum compounds without a metal-carbon linkage
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/08—Antibacterial agents for leprosy
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/04—Amoebicides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/10—Anthelmintics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/10—Anthelmintics
- A61P33/12—Schistosomicides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
General Health & Medical Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Virology (AREA)
Oncology (AREA)
Tropical Medicine & Parasitology (AREA)
Communicable Diseases (AREA)
Engineering & Computer Science (AREA)
Molecular Biology (AREA)
Biotechnology (AREA)
Bioinformatics & Cheminformatics (AREA)
Rheumatology (AREA)
Pain & Pain Management (AREA)
Pulmonology (AREA)
Hematology (AREA)
AIDS & HIV (AREA)
Gastroenterology & Hepatology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Inorganic Compounds Of Heavy Metals (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

AT04809566T 2003-08-13 2004-08-13 Verfahren zur inhibierung der proliferation von tumorzellen, bei dem platinkomplexe eingesetzt werden ATE404574T1 (de)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date
US48122603P	2003-08-13	2003-08-13
US51558003P	2003-10-30	2003-10-30
US51994303P	2003-11-14	2003-11-14
US52529503P	2003-11-25	2003-11-25

Publications (1)

Publication Number	Publication Date
ATE404574T1 true ATE404574T1 (de)	2008-08-15

Family

ID=34199238

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
AT04781131T ATE453653T1 (de)	2003-08-13	2004-08-13	Platinkomplexe zur behandlung von tumoren
AT04809566T ATE404574T1 (de)	2003-08-13	2004-08-13	Verfahren zur inhibierung der proliferation von tumorzellen, bei dem platinkomplexe eingesetzt werden

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
AT04781131T ATE453653T1 (de)	2003-08-13	2004-08-13	Platinkomplexe zur behandlung von tumoren

Country Status (8)

Country	Link
US (6)	US7566798B2 (de)
EP (2)	EP1664070B1 (de)
JP (2)	JP2007502301A (de)
AT (2)	ATE453653T1 (de)
AU (3)	AU2004270655B2 (de)
CA (2)	CA2535584A1 (de)
DE (2)	DE602004015811D1 (de)
WO (2)	WO2005023824A2 (de)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU2004270655B2 (en)	2003-08-13	2011-03-24	University Of South Florida	Methods for inhibiting tumor cell proliferation
US20050288365A1 (en) *	2004-01-06	2005-12-29	Heidi Kay	Platinum complexes and methods for inhibiting tumor cell proliferation
WO2005110477A2 (en) *	2004-04-09	2005-11-24	University Of South Florida	Combination therapies for cancer and proliferative angiopathies
JP2008519859A (ja) *	2004-11-10	2008-06-12	ユニバーシティーオブサウスフロリダ	標的化した薬物送達のための白金錯体
WO2006065894A2 (en) *	2004-12-14	2006-06-22	University Of South Florida	Methods for inhibiting stat3 signaling in immune cells
DE102004060934A1 (de) *	2004-12-17	2006-06-29	Wacker Chemie Ag	Vernetzbare Polyorganosiloxanmassen
ATE488507T1 (de) *	2005-06-30	2010-12-15	Bionumerik Pharmaceuticals Inc	Platinanaloga mit monoazolligand
WO2007006019A1 (en) *	2005-07-06	2007-01-11	University Of South Florida	Materials and methods for screening, diagnosis and prognosis of conditions associated with stat protein expression
WO2007013946A2 (en) *	2005-07-20	2007-02-01	University Of South Florida	Method of predicting responsiveness to chemotherapy and selecting treatments
WO2007047623A2 (en) *	2005-10-14	2007-04-26	University Of South Florida	Methods of inhibiting cell growth and methods of enhancing radiation responses
DE102006040647A1 (de) *	2006-08-30	2008-03-13	Robert Bosch Gmbh	Handwerkzeugmaschine
US8026382B2 (en)	2007-05-18	2011-09-27	Heidi Kay	Lipid raft, caveolin protein, and caveolar function modulation compounds and associated synthetic and therapeutic methods
US8895610B1 (en)	2007-05-18	2014-11-25	Heldi Kay	Platinum (IV) compounds targeting zinc finger domains
WO2008155727A1 (en) *	2007-06-18	2008-12-24	Platco Technologies (Proprietary) Limited	Platinum (iv) complexes
HRP20160625T1 (hr)	2007-09-10	2016-08-12	Boston Biomedical, Inc.	Novi inhibitori stat3 signalnog puta i inhibitori matičnih stanica raka
WO2010067335A1 (en)	2008-12-12	2010-06-17	Platco Technologies (Proprietary) Limited	Platinum (iv) complexes for use in the treatment of proliferative diseases such as cancer
EP3012329B1 (de)	2010-06-18	2017-10-25	Myriad Genetics, Inc.	Verfahren und materialien zur bewertung des verlusts der heterozygotie
WO2012027224A1 (en)	2010-08-24	2012-03-01	Dana-Farber Cancer Institute, Inc.	Methods for predicting anti-cancer response
JP6117194B2 (ja)	2011-06-17	2017-04-19	ミリアド・ジェネティックス・インコーポレイテッド	アレル不均衡を評価するための方法および材料
RU2491936C2 (ru) *	2011-07-11	2013-09-10	Борис Николаевич Анисимов	Способ комплексного лечения больных паразитарными заболеваниями
BR112014015152A2 (pt)	2011-12-21	2017-07-04	Myriad Genetics Inc	métodos e materiais para a avaliação da perda de heterozigosidade
CA2864481C (en)	2012-02-23	2020-07-14	Dana-Farber Cancer Institute, Inc.	Methods for predicting anti-cancer response
WO2013182645A1 (en)	2012-06-07	2013-12-12	Institut Curie	Methods for detecting inactivation of the homologous recombination pathway (brca1/2) in human tumors
US10308986B2 (en)	2013-03-14	2019-06-04	Children's Medical Center Corporation	Cancer diagnosis, treatment selection and treatment
BR112015023568B8 (pt)	2013-03-15	2024-01-02	Ann Mcfarland Sherri	Composto à base de metal como composto fotodinâmico
AU2014248007B2 (en)	2013-04-05	2020-03-26	Myriad Genetics, Inc.	Methods and materials for assessing homologous recombination deficiency
CN104230997B (zh) *	2013-06-13	2017-01-04	上海医药工业研究院	一种铂（ⅱ）配合物、其制备方法、药物组合物及应用
WO2015013565A1 (en) *	2013-07-25	2015-01-29	Nemucore Medical Innovations, Inc.	Platinum derivatives for hydrophobic formulations
WO2015086473A1 (en)	2013-12-09	2015-06-18	Institut Curie	Methods for detecting inactivation of the homologous recombination pathway (brca1/2) in human tumors
CA2958801A1 (en)	2014-08-15	2016-02-18	Myriad Genetics, Inc.	Methods and materials for assessing homologous recombination deficiency
BR112017027277A2 (pt)	2015-06-19	2018-09-04	Syn Nat Products Entpr Llc	?método para o tratamento ou prevenção de uma doença e métodos para matar uma célula?
BR112017027285A2 (pt)	2015-06-19	2018-09-11	Syn Nat Products Entpr Llc	?cocristal, composição farmacêutica e método para o tratamento de uma doença?
US10428099B2 (en)	2015-06-25	2019-10-01	Syn-Nat Products Enterprise LLC	Pharmaceutical co-crystal composition and use thereof
WO2018102427A1 (en)	2016-11-29	2018-06-07	Boston Biomedical, Inc.	Naphthofuran derivatives, preparation, and methods of use thereof
MX2020005310A (es)	2017-11-21	2020-10-08	Medoncare Pharmaceutical Co Ltd	Producto de combinacion que comprende dicicloplatino y metodo de preparacion y uso del mismo.
CN112175014B (zh) *	2020-10-10	2021-08-20	中国药科大学	一种一氧化氮供体型四价铂衍生物、制备方法及其医药用途
EP4141127B1 (de)	2021-08-30	2024-10-09	Zentrum Familiärer Brust- und Eierstockkrebs Universitätsklinik Köln	Verfahren zur bewertung des mangels an homologer rekombination in eierstockkrebszellen
WO2024063828A1 (en)	2022-09-21	2024-03-28	Oracle International Corporation	Expert-optimal correlation: contamination factor identification for unsupervised anomaly detection

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4177263A (en) *	1972-02-28	1979-12-04	Research Corporation	Anti-animal tumor method
GB1432563A (en)	1972-04-10	1976-04-22	Rustenburg Platinum Mines Ltd	Platinum- co-ordination compounds
GR851932B (de) *	1984-08-14	1985-12-13	Engelhard Corp
JPS6296A (ja) *	1985-03-06	1987-01-06	Sumitomo Pharmaceut Co Ltd	脂溶性白金（２）錯体
JPH01156989A (ja) *	1987-09-25	1989-06-20	Ss Pharmaceut Co Ltd	新規白金錯体
EP0328274B1 (de)	1988-02-02	1994-10-19	Johnson Matthey, Inc.,	Pt(IV) Komplexe
JP3520367B2 (ja) *	1994-12-22	2004-04-19	独立行政法人産業技術総合研究所	白金ニトロアンミン系錯体の製造方法
US6008395A (en) *	1995-02-28	1999-12-28	Kidani; Yoshinori	Platinum (IV) complex, production process thereof and carcinostatic agent containing the same
US5922689A (en) *	1995-09-11	1999-07-13	Unitech Pharmaceuticals, Inc.	Cisplatin analogs for cancer treatment
US5849790A (en)	1995-11-17	1998-12-15	The University Of South Florida	(Mono) ethylenediaminenitroplatinum (IV) complexes with ligands of oxides of nitrogen as possible anti-tumor agents
US6145688A (en) *	1996-07-17	2000-11-14	Smith; James C.	Closure device for containers
US5977393A (en)	1997-11-21	1999-11-02	California Institute Of Technology	Schiff base derivatives of ruthenium and osmium olefin metathesis catalysts
KR100246722B1 (ko) *	1997-12-30	2000-04-01	박호군	경구용 백금 착화합물 항암제 및 그 제조방법
JP2002535247A (ja) *	1998-11-26	2002-10-22	ペンタファルムアクチェンゲゼルシャフト	輸送系複合体
EP1146869A2 (de) *	1999-01-27	2001-10-24	University Of South Florida	Inhibierung der stat3 signaltransduktion für krebsbehandlung
US6511676B1 (en) *	1999-11-05	2003-01-28	Teni Boulikas	Therapy for human cancers using cisplatin and other drugs or genes encapsulated into liposomes
US7034109B2 (en) *	2000-10-13	2006-04-25	Christophe Bonny	Intracellular delivery of biological effectors
US7033597B2 (en) *	2000-10-13	2006-04-25	Université de Lausanne	Intracellular delivery of biological effectors
US7638122B2 (en) *	2003-03-07	2009-12-29	University Of South Florida	Stat3 antagonists and their use as vaccines against cancer
WO2005002508A2 (en)	2003-06-11	2005-01-13	Access Pharmaceuticals, Inc.	Macromolecular platinum chelates
AU2004270655B2 (en)	2003-08-13	2011-03-24	University Of South Florida	Methods for inhibiting tumor cell proliferation
US20050288365A1 (en)	2004-01-06	2005-12-29	Heidi Kay	Platinum complexes and methods for inhibiting tumor cell proliferation
JP2008519859A (ja)	2004-11-10	2008-06-12	ユニバーシティーオブサウスフロリダ	標的化した薬物送達のための白金錯体
WO2007006019A1 (en)	2005-07-06	2007-01-11	University Of South Florida	Materials and methods for screening, diagnosis and prognosis of conditions associated with stat protein expression

2004
- 2004-08-13 AU AU2004270655A patent/AU2004270655B2/en not_active Ceased
- 2004-08-13 CA CA002535584A patent/CA2535584A1/en not_active Abandoned
- 2004-08-13 JP JP2006523413A patent/JP2007502301A/ja active Pending
- 2004-08-13 JP JP2006523414A patent/JP2007502777A/ja active Pending
- 2004-08-13 EP EP04809566A patent/EP1664070B1/de not_active Expired - Lifetime
- 2004-08-13 US US10/918,769 patent/US7566798B2/en not_active Expired - Fee Related
- 2004-08-13 DE DE602004015811T patent/DE602004015811D1/de not_active Expired - Lifetime
- 2004-08-13 AU AU2004264421A patent/AU2004264421B2/en not_active Ceased
- 2004-08-13 DE DE602004024909T patent/DE602004024909D1/de not_active Expired - Lifetime
- 2004-08-13 WO PCT/US2004/026392 patent/WO2005023824A2/en not_active Ceased
- 2004-08-13 WO PCT/US2004/026393 patent/WO2005016946A2/en not_active Ceased
- 2004-08-13 CA CA002535762A patent/CA2535762A1/en not_active Abandoned
- 2004-08-13 US US10/918,762 patent/US7238372B2/en not_active Expired - Lifetime
- 2004-08-13 AT AT04781131T patent/ATE453653T1/de not_active IP Right Cessation
- 2004-08-13 EP EP04781131A patent/EP1675864B1/de not_active Expired - Lifetime
- 2004-08-13 AT AT04809566T patent/ATE404574T1/de not_active IP Right Cessation
2007
- 2007-01-31 US US11/701,907 patent/US7763585B2/en not_active Expired - Fee Related
2009
- 2009-07-21 US US12/506,913 patent/US7759510B2/en not_active Expired - Fee Related
2010
- 2010-07-13 US US12/835,114 patent/US8247445B2/en not_active Expired - Fee Related
- 2010-07-15 US US12/837,046 patent/US8598230B2/en not_active Expired - Fee Related
2011
- 2011-05-23 AU AU2011202386A patent/AU2011202386A1/en not_active Abandoned

Also Published As

Publication number	Publication date
US8598230B2 (en)	2013-12-03
US7759510B2 (en)	2010-07-20
US7566798B2 (en)	2009-07-28
US20100316704A1 (en)	2010-12-16
US20090285884A1 (en)	2009-11-19
AU2004264421A1 (en)	2005-02-24
WO2005023824A3 (en)	2005-06-09
US20100310645A1 (en)	2010-12-09
AU2004264421B2 (en)	2011-02-24
CA2535762A1 (en)	2005-03-17
US20050074502A1 (en)	2005-04-07
AU2011202386A1 (en)	2011-06-09
US20050080131A1 (en)	2005-04-14
WO2005016946A2 (en)	2005-02-24
DE602004024909D1 (de)	2010-02-11
WO2005023824A2 (en)	2005-03-17
US20080187992A1 (en)	2008-08-07
EP1675864A2 (de)	2006-07-05
WO2005016946A3 (en)	2005-09-29
JP2007502777A (ja)	2007-02-15
EP1664070A2 (de)	2006-06-07
US8247445B2 (en)	2012-08-21
CA2535584A1 (en)	2005-02-24
JP2007502301A (ja)	2007-02-08
AU2004270655B2 (en)	2011-03-24
EP1664070B1 (de)	2008-08-13
US7763585B2 (en)	2010-07-27
DE602004015811D1 (de)	2008-09-25
US7238372B2 (en)	2007-07-03
AU2004270655A1 (en)	2005-03-17
EP1675864B1 (de)	2009-12-30
ATE453653T1 (de)	2010-01-15

Legal Events

Date	Code	Title	Description
2009-02-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
ATE404574T1 (de)	2008-08-15	Verfahren zur inhibierung der proliferation von tumorzellen, bei dem platinkomplexe eingesetzt werden
ATE471334T1 (de)	2010-07-15	Phosphoramidatderivate von nukleosidverbindungen zur verwendung bei der behandlung von krebs
ATE447965T1 (de)	2009-11-15	Muc1 extrazelluläre domäne und zusammensetzungen für krebsbehandlung, und davon abgeleitete verfahren
DE602006014843D1 (de)	2010-07-22	Verwendung von hif 1alfa modulatoren zur behandlung von krebs
EA200601554A1 (ru)	2006-12-29	Замещенные индол-о-глюкозиды
ATE419253T1 (de)	2009-01-15	Inhibitoren von thienopyridin- und furopyridinkinase
ATE554087T1 (de)	2012-05-15	Neue kinaseinhibitoren
DE602005021684D1 (de)	2010-07-15	Verfahren zur herstellung von pimecrolimus
DE69914085D1 (de)	2004-02-12	Verwendung von aryl- (oder heteroaryl-) azoylcarbinolderivaten zur behandlung von durch überschuss von substanz p hervorgerufenen beschwerden
ATE435209T1 (de)	2009-07-15	Verfahren zur herstellung von montelukast-natrium
ATE431426T1 (de)	2009-05-15	Verfahren zur identifizierung von lrrk2 interagierenden molekülen und zur reinigung von lrrk2
WO2006034113A3 (en)	2006-08-24	Quinolone analogs as cell proliferation inhibitors
WO2003084475A3 (en)	2005-04-14	INHIBITORS OF THE S100-p53 PROTEIN-PROTEIN INTERACTION AND METHOD OF INHIBITING CANCER EMPLOYING THE SAME
MX2010005324A (es)	2010-06-01	Composiciones y metodos para inhibir el avance del tumor.
DK1773420T3 (da)	2011-01-10	Anvendelse af gingivale fibroblaster til vaskulær celleterapi
ATE397000T1 (de)	2008-06-15	Tetrahydropyridothiophenen zur verwendung in der behandlung von krebs
WO2004045545A3 (en)	2004-08-12	Compositions and methods for the treatment of cancer, screening of putative anti-cancer compounds, and assessing cancer progression
TW200716132A (en)	2007-05-01	Novel chemical compounds
MXPA05001690A (es)	2005-10-19	Estrategia de deteccion para farmacos anticancer.
ATE423129T1 (de)	2009-03-15	Inhibitoren von lyn-verbundener signaltransduktion (last) und deren verwendung zur behandlung von prostatakrebs
WO2005086909A3 (en)	2006-01-19	Protein kinase c iota
WO2006091965A3 (en)	2007-01-18	Nod1 as an anti-tumor agent
WO2004096021A3 (en)	2004-12-09	Global analysis of transposable elements as molecular markers of cancer
DE602005015329D1 (de)	2009-08-20	Rutheniumkomplexe zur krebsbehandlung
ATE525073T1 (de)	2011-10-15	Verwendung von pyrimidylaminobenzamiden zur behandlung von durch modulation einer tie-2 kinase-aktivität verursachten krankheiten